direct oral anticoagulant (DAO)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial result

acute coronary syndrome

apixaban
APPRAISE-1 (10mg od), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE-1 (2.5 mg bid), 2009      NCTapixabanplaceboLow risk of bias negative
APPRAISE 2, 2011      NCTapixabanplaceboLow risk of bias negative
dabigatran
REDEEM, 2009    NCTdabigatranplaceboLow risk of bias negative
otamixaban
SEPIA-ACS1 TIMI 42, 2009    NCTotamixabanunfractionated heparinLow risk of bias suggesting
rivaroxaban
ATLAS ACS 2 - TIMI 51 (2.5mg), 2011      NCTrivaroxaban 2.5mgplaceboLow risk of bias suggesting
ATLAS ACS-TIMI 46 (2.5mg), 2009      NCTrivaroxaban 2.5mgplaceboLow risk of bias negative
ATLAS ACS 2 - TIMI 51 (5mg), 2011      NCTrivaroxaban 5mgplacebosuggesting
ATLAS ACS-TIMI 46 (5mg), 2009      NCTrivaroxaban 5mgplaceboLow risk of bias negative
ximelagatran
ESTEEM, 2003   ximelagatranplaceboExploratory -

atrial fibrillation

apixaban
ARISTOTLE, 2011        NCTapixabanwarfarin standard doseLow risk of bias conclusive
phase 2 apixaban    NCTapixabanwarfarin standard doseExploratory -
dabigatran
phase 2 dabigatran    NCTdabigatranwarfarin standard doseExploratory -
RE-LY (110mg), 2009      NCTdabigatran 110mgwarfarin standard doseRisk of bias suggesting
PETRO (150mg), 2007     dabigatran 150mgwarfarin standard doseExploratory -
RE-LY (150mg), 2009      NCTdabigatran 150mgwarfarin standard doseRisk of bias suggesting
edoxaban
Weitz (edoxaban phase 2)    NCTedoxabanwarfarin standard doseExploratory -
phase 2 edoxaban    NCTedoxabanwarfarin standard doseExploratory -
ENGAGE-AF TIMI 48 High dose, 2013    NCTedoxaban high dosewarfarin standard doseLow risk of bias suggesting
idraparinux
AMADEUS, 2008      NCTidraparinuxwarfarin standard doseRisk of bias negative
rivaroxaban
ROCKET-AF, 2010        NCTrivaroxabanwarfarin standard doseLow risk of bias suggesting
ximelagatran
SPORTIF II (ximelagatran vs warfarin standard dose), 2002     ximelagatranwarfarin standard doseRisk of bias -
SPORTIF III, 2003     ximelagatranwarfarin standard doseRisk of bias suggesting
SPORTIF V, 2005       ximelagatranwarfarin standard doseLow risk of bias suggesting

cardiovascular prevention

rivaroxaban
COMPASS (rivaroxaban alone), 2017    NCTrivaroxabanaspirinsecondary prevention -
COMPASS (rivaroxaban + aspirin), 2017      NCTrivaroxaban + aspirinaspirinsecondary preventionLow risk of bias -

thrombosis prevention

apixaban
ADOPT, 2011      NCTapixabanenoxaparinmedical patientsLow risk of bias suggesting
ADVANCE 3, 2010    NCTapixabanenoxaparinhip surgeryLow risk of bias suggesting
ADVANCE 2, 2010      NCTapixabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting
APROPOS 2.5mg, 2007    NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias negative
ADVANCE-1, 2008      NCTapixabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting
betrixaban
APEX, 2016    NCTbetrixabanenoxaparinmedical patientsLow risk of bias suggesting
dabigatran
RE-NOVATE (150mg), 2007      NCTdabigatran 150mgenoxaparinhip surgeryLow risk of bias negative
RE-NOVATE (220mg), 2007      NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-NOVATE 2    NCTdabigatran 220mgenoxaparinhip surgeryLow risk of bias negative
RE-MODEL (150mg), 2007     dabigatran 150mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative
RE-MODEL (220mg), 2007   dabigatran 220mgenoxaparin (europe regimen)knee surgeryLow risk of bias negative
RE-MOBILIZE (150mg), 2008     dabigatran 150mgenoxaparin (US regimen)knee surgeryLow risk of bias negative
RE-MOBILIZE (220mg), 2008     dabigatran 220mgenoxaparin (US regimen)knee surgeryLow risk of bias negative
edoxaban
STARS J-V    NCTedoxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
rivaroxaban
RECORD 1, 2008      NCTrivaroxabanenoxaparinhip surgeryLow risk of bias suggesting
RECORD 3, 2008    NCTrivaroxabanenoxaparin (europe regimen)knee surgeryLow risk of bias suggesting
ODIXa-HIP 10mg, 2006   rivaroxabanenoxaparin (short duration)hip surgeryLow risk of bias suggesting
RECORD 2, 2008    NCTrivaroxaban (long duration)enoxaparin (short duration)hip surgeryLow risk of bias suggesting
ODIXa-KNEE, 2005   rivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias negative
RECORD 4, 2009    NCTrivaroxabanenoxaparin (US regimen)knee surgeryLow risk of bias suggesting

venous thrombosis

apixaban
AMPLIFY-EXT 2.5mg, 2012      NCTapixaban 2.5mgdiscontinuationLow risk of bias suggesting
AMPLIFY-EXT 5mg, 2012      NCTapixaban 5mgdiscontinuationLow risk of bias suggesting
Botticelli DVT, 2008      NCTapixaban (without LMWH)LMWH/VKAExploratory -
AMPLIFY, 2013      NCTapixaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting
dabigatran
RE-MEDY, 2011      NCTdabigatranwarfarinLow risk of bias suggesting
RE-SONATE, 2011    NCTdabigatrandiscontinuationLow risk of bias suggesting
RE-COVER, 2009      NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting
RE-COVER II, 2011    NCTheparin/dabigatranheparin/VKA heparin - DOAC Low risk of bias suggesting
edoxaban
Edoxaban Hokusai VTE, 2013      NCTheparin/edoxabanheparin/VKA heparin - DOAC Low risk of bias suggesting
rivaroxaban
EINSTEIN-extension, 2009    NCTrivaroxabandiscontinuationLow risk of bias suggesting
Einstein-DVT Dose-Ranging Study, 2008     rivaroxaban (without LMWH)LMWH/VKA -
Einstein-DVT Evaluation, 2010    NCTrivaroxaban (without LMWH)LMWH/VKA DOAC without heparin Low risk of bias suggesting
Einstein-PE Evaluation, 2012      NCTrivaroxaban (without LMWH)LMWH/VKARisk of bias -
rosuvastatin
VanGogh extension, 2007      NCTidraparinuxdiscontinuationsuggesting
ximelagatran
THRIVE III, 2003       ximelagatrandiscontinuationLow risk of bias suggesting
THRIVE I, 2003   ximelagatran (without LMWH)LMWH/VKA -